CPRX
NASDAQCatalyst Pharmaceuticals Inc.
Price$31.27+6.58 (+26.65%)
2026-03-042026-06-05
News · 26 weeks40-85%
2025-12-142026-06-07
Mix1790d
- SEC Filings9(53%)
- Other4(24%)
- Earnings3(18%)
- Insider1(6%)
Latest news
25 items- INSIDERChief Medical Officer Andrews William T. converted options into 3,052 shares and covered exercise/tax liability with 743 shares (SEC Form 4) (withholding tax)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- SECSEC Form PREM14A filed by Catalyst Pharmaceuticals Inc.PREM14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form DEFA14A filed by Catalyst Pharmaceuticals Inc.DEFA14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form 8-K filed by Catalyst Pharmaceuticals Inc.8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals Reports First Quarter 2026 Financial ResultsDelivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data) Product Revenue, net$149,343$141,400 5.6%FIRDAPSE Product Revenue, net$98,859$83,731 18.1%AGAMREE Product Revenu
- SECSEC Form 10-Q filed by Catalyst Pharmaceuticals Inc.10-Q - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form DEFA14A filed by Catalyst Pharmaceuticals Inc.DEFA14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form DEFA14A filed by Catalyst Pharmaceuticals Inc.DEFA14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and WebcastCORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac
- SECSEC Form DEFA14A filed by Catalyst Pharmaceuticals Inc.DEFA14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECCatalyst Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement ("Agreement") with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private
- PRAngelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare DiseaseThe Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026 ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A. ("Angelini Pharma"), an international pharmaceutica
- SECAmendment: SEC Form 10-K/A filed by Catalyst Pharmaceuticals Inc.10-K/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. Catalyst's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:May 12, 2026Time:8:30 AM ETUS/Canada Dial-in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Catalyst Pharmaceuticals Inc.SCHEDULE 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
- SECSEC Form 8-K filed by Catalyst Pharmaceuticals Inc.8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific ConferenceCORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals. "The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping
- SECSEC Form 8-K filed by Catalyst Pharmaceuticals Inc.8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial GuidanceFull Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuti
- SECSEC Form 10-K filed by Catalyst Pharmaceuticals Inc.10-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- PRCatalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare ConferenceCORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida. Presentation DetailsDate: Tuesday, March 10, 2026Presentation: 3:30 PM ETWebcast Link The webcast will be available under the Inv
- INSIDERChief HR Officer Russo Gregg covered exercise/tax liability with 211 shares and converted options into 687 shares (SEC Form 4)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- PRCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results after the market close on Wednesday, February 25, 2026. Catalyst's management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:February 26, 2026Tim
- SECCatalyst Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
CPRX FAQ
7 questionsWhat does Catalyst Pharmaceuticals Inc. do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3...Where does CPRX stock trade?
Catalyst Pharmaceuticals Inc. (CPRX) is listed on NASDAQ.What sector and industry is CPRX in?
Catalyst Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Catalyst Pharmaceuticals Inc. go public?
Catalyst Pharmaceuticals Inc. (CPRX) completed its IPO in 2006.What are analysts saying about CPRX?
Catalyst Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $2800.00 price target on 2025-02-04. Recent price targets range from $1200.00 to $3500.00.What companies are similar to CPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CPRX side-by-side with any of them on Quantisnow.How can I track CPRX on Quantisnow?
Quantisnow aggregates Catalyst Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CPRX to receive live email and push alerts on every new disclosure.